{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=25", "query": { "intervention": "MCG", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 3096, "total_pages": 310, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T23:33:13.447Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03488251", "title": "PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-hodgkin Lymphoma,B Cell", "Refractory Diffuse Large B-Cell Lymphoma", "Relapsed Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "MT-3724", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-08-20", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2022-08-16", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 9, "location_summary": "Orange, California • Santa Monica, California • Whittier, California + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03488251" }, { "nct_id": "NCT01189396", "title": "Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma", "Bronchospasm", "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "A006", "type": "DRUG" }, { "name": "Placebo DPI", "type": "DRUG" }, { "name": "Proventil-HFA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amphastar Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2010-07", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 4, "location_summary": "Medford, Oregon • Portland, Oregon • San Antonio, Texas + 1 more", "locations": [ { "city": "Medford", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189396" }, { "nct_id": "NCT06942442", "title": "A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HLA-A*0201 Positive Cells Present", "Clear Cell Sarcoma (CCS)" ], "interventions": [ { "name": "Physician's Choice", "type": "DRUG" }, { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2025-10-22", "completion_date": "2030-10-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 3, "location_summary": "Los Angeles, California • Chicago, Illinois • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942442" }, { "nct_id": "NCT01455857", "title": "A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "ITCA 650", "type": "DRUG" }, { "name": "ITCA placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 460, "start_date": "2013-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-08-18", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455857" }, { "nct_id": "NCT03012061", "title": "Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "Fluticasone Furoate", "type": "DRUG" }, { "name": "Albuterol/salbutamol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 425, "start_date": "2017-01-25", "completion_date": "2018-05-30", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 19, "location_summary": "Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Natchitoches", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012061" }, { "nct_id": "NCT05147805", "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Treprostinil Palmitil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 102, "start_date": "2022-08-24", "completion_date": "2025-03-27", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05147805" }, { "nct_id": "NCT02268253", "title": "Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Tagraxofusp Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemline Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2016-02-10", "completion_date": "2023-03-27", "has_results": true, "last_update_posted_date": "2025-01-06", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 22, "location_summary": "Clovis, California • Duarte, California • Los Angeles, California + 18 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02268253" }, { "nct_id": "NCT00302003", "title": "Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Favorable Prognosis Hodgkin Lymphoma", "Childhood Lymphocyte Depletion Hodgkin Lymphoma", "Childhood Mixed Cellularity Hodgkin Lymphoma", "Childhood Nodular Sclerosis Hodgkin Lymphoma", "Stage I Childhood Hodgkin Lymphoma", "Stage II Childhood Hodgkin Lymphoma" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 287, "start_date": "2006-02", "completion_date": "2019-06-30", "has_results": true, "last_update_posted_date": "2021-03-30", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00302003" }, { "nct_id": "NCT04992442", "title": "Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-935 Oral Tablet", "type": "DRUG" }, { "name": "[14C]TAK-935 IV Infusion", "type": "DRUG" }, { "name": "[14C]TAK-935 Oral Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "19 Years to 55 Years · Male only" }, "enrollment_count": 6, "start_date": "2020-07-09", "completion_date": "2020-08-18", "has_results": true, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04992442" }, { "nct_id": "NCT01857323", "title": "Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma", "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "Albuterol Spiromax®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 317, "start_date": "2013-05", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-26T23:33:13.447Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Costa Mesa, California • Huntington Beach, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01857323" } ] }